Literature DB >> 8006430

The spectrum of Stevens-Johnson syndrome and toxic epidermal necrolysis: a clinical classification.

J C Roujeau1.   

Abstract

The nosology of severe bullous erythema multiforme (EM), Stevens-Johnson syndrome (SJS), and toxic epidermal necrolysis (TEN) remains controversial. To conduct a prospective case-control study of the etiologic factors of these diseases, we needed to define criteria for classifying the cases. After having reviewed photographs of the skin lesions of more than 200 patients, an international group of dermatologists proposed a classification based on the pattern of "EM-like lesions" (categorized as typical targets, raised or flat atypical targets, and purpuric macules) and on the extent of epidermal detachment. The "consensus" classification in five categories was as follows: bullous erythema multiforme, detachment below 10% of the body surface area (BSA) plus localized typical targets or raised atypical targets; SJS, detachment below 10% of the BSA plus widespread erythematous or purpuric macules or flat atypical targets; overlap SJSTEN, detachment between 10% and 30% of the BSA plus widespread purpuric macules or flat atypical targets; TEN with spots, detachment above 30% of the BSA plus wide-spread purpuric macules or flat atypical targets; TEN without spots, detachment above 10% of the BSA with large epidermal sheets and without any purpuric macules or target. Whether all five categories proposed represent distinct etiopathologic entities will require further epidemiologic and laboratory investigations.

Entities:  

Mesh:

Year:  1994        PMID: 8006430     DOI: 10.1111/1523-1747.ep12388434

Source DB:  PubMed          Journal:  J Invest Dermatol        ISSN: 0022-202X            Impact factor:   8.551


  39 in total

1.  Evaluation of the patients diagnosed with Stevens Johnson syndrome and toxic epidermal necrolysis: a single center experience.

Authors:  Şükrü Çekiç; Yakup Canıtez; Nihat Sapan
Journal:  Turk Pediatri Ars       Date:  2016-09-01

Review 2.  Expectations, validity, and reality in pharmacogenetics.

Authors:  Nita A Limdi; David L Veenstra
Journal:  J Clin Epidemiol       Date:  2009-12-07       Impact factor: 6.437

3.  Clinical, etiologic, and histopathologic features of Stevens-Johnson syndrome during an 8-year period at Mayo Clinic.

Authors:  David A Wetter; Michael J Camilleri
Journal:  Mayo Clin Proc       Date:  2010-02       Impact factor: 7.616

4.  Toxic epidermal necrolysis and Stevens-Johnson syndrome are induced by soluble Fas ligand.

Authors:  Riichiro Abe; Tadamichi Shimizu; Akihiko Shibaki; Hideki Nakamura; Hirokazu Watanabe; Hiroshi Shimizu
Journal:  Am J Pathol       Date:  2003-05       Impact factor: 4.307

5.  EMPACT syndrome: limited evidence despite a high-risk cohort.

Authors:  Andrew J Bishop; Maria Chang; Mario E Lacouture; Christopher A Barker
Journal:  J Neurooncol       Date:  2014-05-03       Impact factor: 4.130

6.  Strong association between HLA-B*1502 and carbamazepine-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in mainland Han Chinese patients.

Authors:  Yan Zhang; Jin Wang; Li-Mei Zhao; Wei Peng; Guo-Qing Shen; Ling Xue; Xiao-Xian Zheng; Xiao-Jing He; Chun-Yan Gong; Li-Yan Miao
Journal:  Eur J Clin Pharmacol       Date:  2011-03-19       Impact factor: 2.953

7.  HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol.

Authors:  Shuen-Iu Hung; Wen-Hung Chung; Lieh-Bang Liou; Chen-Chung Chu; Marie Lin; Hsien-Ping Huang; Yen-Ling Lin; Joung-Liang Lan; Li-Cheng Yang; Hong-Shang Hong; Ming-Jing Chen; Ping-Chin Lai; Mai-Szu Wu; Chia-Yu Chu; Kuo-Hsien Wang; Chien-Hsiun Chen; Cathy S J Fann; Jer-Yuarn Wu; Yuan-Tsong Chen
Journal:  Proc Natl Acad Sci U S A       Date:  2005-03-02       Impact factor: 11.205

Review 8.  Amniotic membrane transplantation as a new therapy for the acute ocular manifestations of Stevens-Johnson syndrome and toxic epidermal necrolysis.

Authors:  Elizabeth Shay; Ahmad Kheirkhah; Lingyi Liang; Hossam Sheha; Darren G Gregory; Scheffer C G Tseng
Journal:  Surv Ophthalmol       Date:  2009-08-21       Impact factor: 6.048

Review 9.  Drug-induced severe skin reactions. Incidence, management and prevention.

Authors:  P Wolkenstein; J Revuz
Journal:  Drug Saf       Date:  1995-07       Impact factor: 5.606

10.  Dermatological conditions in intensive care: a secondary analysis of the Intensive Care National Audit and Research Centre (ICNARC) Case Mix Programme database.

Authors:  Susannah M C George; David A Harrison; Catherine A Welch; Kathleen M Nolan; Peter S Friedmann
Journal:  Crit Care       Date:  2008-01-18       Impact factor: 9.097

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.